In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, has announced the completion of its seed financing round. Led by Manifestations Capital in collaboration with Notley Ventures and numerous industry veterans and thought leaders, this
Read More
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational New Drug (Pre-IND) meeting by the U.S. Food and Drug Administration (FDA) for new chemical entity Triptax™. Biomind Labs is devoted to crafting innovative pharmaceuticals for patients with neurological and psychiatric disorders, using
Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that
Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently
In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, has announced the completion
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational
Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel
Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for
atai has administered the first dosage of their VLS-01 synthetic DMT drug in their Phase 1 single-ascending dose (SAD) trial, with topline
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual
Leading psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) has announced the completion of dose administration to 30
Revitalist Lifestyle and Wellness LTD. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) recently announced a new joint venture partnership with Wake Network, Inc.
Psychedelic biotechnology company Bright Minds Biosciences recently announced that it has dosed the first patient in a Phase I trial (NCT 05397041)
Drug discovery and development company Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced today the company has identified three additional families
